The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
The Peroxisome Proliferator-Activated Receptor-γ Agonist Rosiglitazone Decreases Bone Formation and Bone Mineral Density in Healthy Postmenopausal Women: A Randomized, Controlled Trial
Abstract
CONTEXT: Thiazolidinediones, which are peroxisome proliferator-activated receptor-gamma agonists, are widely prescribed to patients with disorders characterized by insulin resistance. Preclinical studies suggest that peroxisome proliferator-activated receptor-gamma signaling negatively regulates bone formation and bone density. Human data on the skeletal effects of thiazolidinediones are currently available only from observational studies. OBJECTIVE: The objective of the study was to determine whether rosiglitazone, a thiazolidinedione, inhibits bone formation. DESIGN: The study was a 14-wk randomized, double-blind, placebo-controlled trial. SETTING: The study was conducted in the general community. PATIENTS: Fifty healthy, postmenopausal women participated in the study. INTERVENTION: Intervention was rosiglitazone 8 mg/d. MAIN OUTCOME MEASURES: The primary end point was biochemical markers of bone formation, and secondary end points were a bone resorption marker and bone mineral density. RESULTS: The osteoblast markers procollagen type I N-terminal propeptide and osteocalcin declined by 13% (P<0.005 vs. placebo) and 10% (P=0.04 vs. placebo), respectively, in the rosiglitazone group. These changes were evident by 4 wk and persisted for the duration of the study. There was no change in the serum beta-C-terminal telopeptide of type I collagen, a marker of bone resorption (P=0.9 vs. placebo). Total hip bone density fell in the rosiglitazone group (mean change from baseline rosiglitazone -1.9%, placebo -0.2%; between-group difference 1.7%, 95% confidence interval 0.6-2.7, P<0.01); lumbar spine bone density fell significantly from baseline values in the rosiglitazone group (P=0.02 vs. baseline) but was not significantly different between groups (mean change from baseline rosiglitazone -1.2%, placebo -0.2%; between-group difference 1.0%, 95% confidence interval -0.2-2.3, P=0.13). CONCLUSIONS: Short-term therapy with rosiglitazone exerts detrimental skeletal effects by inhibiting bone formation. Skeletal end points should be included in future long-term studies of thiazolidinedione use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Ehrmann, D. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041536 · Cited by 1,881
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
PPAR γ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors
Akune, T., Ohba, S., Kamekura, S., Yamaguchi, M., Chung, U.-I., Kubota, N., Terauchi, Y., Harada, Y., Azuma, Y., Nakamura, K., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19900 · Cited by 869
Therapeutic roles of peroxisome proliferator-activated receptor agonists
Staels, B., & Fruchart, J.-C. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2460 · Cited by 646
Risk of Fracture in Women with Type 2 Diabetes: the Women’s Health Initiative Observational Study
Bonds, D. E., Larson, J. C., Schwartz, A. V., Strotmeyer, E. S., Robbins, J., Rodriguez, B. L., Johnson, K. C., & Margolis, K. L. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0614 · Cited by 611
Type 1 and Type 2 Diabetes and Incident Hip Fractures in Postmenopausal Women
Nicodemus, K. K., & Folsom, A. R. (2001) · Diabetes Care · doi:10.2337/diacare.24.7.1192 · Cited by 568
Vestergaard, P., Rejnmark, L., & Mosekilde, L. (2005) · Diabetologia · doi:10.1007/s00125-005-1786-3 · Cited by 557
Research works printed but not linked: 3
- Truxillo C, Maximum likelihood parameter estimation with incomplete data. SAS Users Group International Conference, Philadelphia, PA, 2005 (http://www2.sas.com/proceedings/sugi30/111-30.pdf)
- Jennermann, 1995, Effects of thiazolidinediones on bone turnover in the rat, J Bone Miner Res, 10, S241
- Syversen, 2003, PPAR-α agonists increase bone mineral density in female rats, J Bone Miner Res, 18, S42
Cited by
Pathogenesis of non-alcoholic fatty liver disease
Dowman, J. K., Tomlinson, J. W., & Newsome, P. N. (2010) · QJM · doi:10.1093/qjmed/hcp158 · Cited by 741
Shared and distinct mechanisms of fibrosis
Distler, J. H. W., Györfi, A.-H., Ramanujam, M., Whitfield, M. L., Königshoff, M., & Lafyatis, R. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0322-7 · Cited by 637
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
Loke, Y. K., Singh, S., & Furberg, C. D. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.080486 · Cited by 551
Rosiglitazone-Associated Fractures in Type 2 Diabetes
Kahn, S. E., Zinman, B., Lachin, J. M., Haffner, S. M., Herman, W. H., Holman, R. R., Kravitz, B. G., Yu, D., Heise, M. A., Aftring, R. P., et al. (2008) · Diabetes Care · doi:10.2337/dc07-2270 · Cited by 537
Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation
Choi, J. H., Banks, A. S., Kamenecka, T. M., Busby, S. A., Chalmers, M. J., Kumar, N., Kuruvilla, D. S., Shin, Y., He, Y., Bruning, J. B., et al. (2011) · Nature · doi:10.1038/nature10383 · Cited by 536
PPAR-γ regulates osteoclastogenesis in mice
Wan, Y., Chong, L.-W., & Evans, R. M. (2007) · Nature Medicine · doi:10.1038/nm1672 · Cited by 517
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention
Peters, J. M., Shah, Y. M., & Gonzalez, F. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3214 · Cited by 492
Relationships between fat and bone
Reid, I. R. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0492-z · Cited by 475
Self-citationBone, sweet bone—osteoporotic fractures in diabetes mellitus
Hamann, C., Kirschner, S., Günther, K.-P., & Hofbauer, L. C. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.233 · Cited by 380
Reid, I. R. (2010) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.06.027 · Cited by 367
Self-citationUse of Thiazolidinediones and Fracture Risk
Meier, C., Kraenzlin, M. E., Bodmer, M., Jick, S. S., Jick, H., & Meier, C. R. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.8.820 · Cited by 355
for the National Bone Health Alliance Bone Turnover Marker Project, Szulc, P., Naylor, K., Hoyle, N. R., Eastell, R., & Leary, E. T. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4082-4 · Cited by 327
PPARγ: a circadian transcription factor in adipogenesis and osteogenesis
Kawai, M., & Rosen, C. J. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.155 · Cited by 323
Targeting TGF-β signaling for the treatment of fibrosis
Györfi, A. H., Matei, A.-E., & Distler, J. H. W. (2018) · Matrix Biology · doi:10.1016/j.matbio.2017.12.016 · Cited by 274
New insights into osteoporosis: the bone–fat connection
Kawai, M., de Paula, F. J. A., & Rosen, C. J. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02564.x · Cited by 273
Risk of fracture with thiazolidinediones: An updated meta-analysis of randomized clinical trials
Zhu, Z.-N., Jiang, Y.-F., & Ding, T. (2014) · Bone · doi:10.1016/j.bone.2014.08.010 · Cited by 253
How safe is the use of thiazolidinediones in clinical practice?
Rizos, C., Elisaf, M., Mikhailidis, D., & Liberopoulos, E. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330802597821 · Cited by 161
Billington, E. O., Grey, A., & Bolland, M. J. (2015) · Diabetologia · doi:10.1007/s00125-015-3660-2 · Cited by 133
Self-citationPioglitazone and Risk for Bone Fracture: Safety Data from a Randomized Clinical Trial
Viscoli, C. M., Inzucchi, S. E., Young, L. H., Insogna, K. L., Conwit, R., Furie, K. L., Gorman, M., Kelly, M. A., Lovejoy, A. M., Kernan, W. N., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3237 · Cited by 124
Systematic review and statistical analysis of the integrity of 33 randomized controlled trials
Bolland, M. J., Avenell, A., Gamble, G. D., & Grey, A. (2016) · Neurology · doi:10.1212/wnl.0000000000003387 · Cited by 106
Self-citationAcarbose: oral antidiabetes drug with additional cardiovascular benefits
Hanefeld, M., & Schaper, F. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.2.153 · Cited by 87
Effects of TZD use and discontinuation on fracture rates in ACCORD bone study
Schwartz, A. V., Chen, H., Ambrosius, W. T., Sood, A., Josse, R. G., Bonds, D. E., Schnall, A. M., Vittinghoff, E., Bauer, D. C., Banerji, M. A., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1215 · Cited by 85
Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?
Consoli, A., & Formoso, G. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12101 · Cited by 76
Bouhlel, M. A., Staels, B., & Chinetti‐Gbaguidi, G. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01892.x · Cited by 51
Bone, H. G., Lindsay, R., McClung, M. R., Perez, A. T., Raanan, M. G., & Spanheimer, R. G. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4096 · Cited by 47
Grey, A., Bolland, M., Fenwick, S., Horne, A., Gamble, G., Drury, P. L., & Reid, I. R. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0793 · Cited by 43
Self-citationBolland, M. J., Gamble, G. D., Avenell, A., & Grey, A. (2019) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2019.03.001 · Cited by 31
Self-citationBolland, M. J., Gamble, G. D., Avenell, A., Grey, A., & Lumley, T. (2019) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2019.05.006 · Cited by 27
Self-citation
Metadata
- Authors
- Grey, A., Bolland, M., Gamble, G., Wattie, D., Horne, A., Davidson, J., & Reid, I. R.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2007-04-01
- Volume
- 92
- Issue
- 4
- Pages
- 1305-1310
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1976942305
- Cited by
- 401
- References
- 42
- FWCI
- 49.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.